Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are up 6.18%.
Jazz Pharmaceuticals, Inc. Earnings Cheat Sheet
Results: Adjusted Earnings Per Share increased 50.55% to $1.37 in the quarter versus EPS of $0.91 in the year-earlier quarter.
Revenue: Rose 80.98% to $196.2 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: Jazz Pharmaceuticals, Inc. reported adjusted EPS income of $1.37 per share. By that measure, the company beat the mean analyst estimate of $1.35. It beat the average revenue estimate of $189.92 million.
Quoting Management: “During the first quarter, we continued to deliver strong top and bottom line growth fueled by growing sales of Xyrem and Erwinaze,” said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals plc. “We have made substantial progress in the execution of our strategy to maximize the potential of our product portfolio while further strengthening our cash position, positioning us to pursue promising corporate development opportunities and share repurchases.”
Key Stats (on next page)…
Revenue increased 6.8% from $183.7 million in the previous quarter. EPS decreased 10.46% from $1.53 in the previous quarter.
Looking Forward: Analysts have a more positive outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has risen from a profit of $1.4 to a profit $1.46. For the current year, the average estimate has moved up from a profit of $5.71 to a profit of $5.87 over the last ninety days.
Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)